This guidance will fully update the following:
Status In progress
Developed As CG

Provisional Schedule

Draft guidance consultation 02 January 2018 - 12 February 2018
Expected publication 06 June 2018

Project Team

Developer NICE Clinical Guidelines Team

Email enquiries


Key events during the development of the guidance:

Date Update
21 June 2017 Committee meeting: Subgroup 6
25 May 2017 Committee meeting: 15
15 May 2017 Stakeholder list updated
09 May 2017 Committee meeting: Subgroup 5
11 April 2017 Committee meeting: 14
06 April 2017 Committee list updated
12 September 2016 Committee meeting
06 May 2016 Consultation comments published
27 April 2016 Equality impact assessment published
08 February 2016 - 07 March 2016 Addendum consultation
08 February 2016 We are currently updating our guideline on Dementia: supporting people with dementia and their carers in health and social care (CG42). This update will incorporate the technology appraisal (TA) on Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217). It has been agreed to separately update the first and third bullets of recommendation 1.3 of the TA The updated sections of the recommendation will be published separately as an addendum to TA217. When the full update of CG42 is produced, this addendum will then be incorporated into the guideline.
21 January 2016 Scope published
08 July 2015 - 05 August 2015 Draft scope consultation

For further information on the guideline development process, please read how we develop NICE guidelines